Comparison · Pregnancy Smart
Nirsevimab vs Palivizumab for RSV: What Changed
How do the options compare?
Options are stacked on five dimensions relevant to pregnancy use: mainstream OB guidance, pregnancy-specific evidence, dosing predictability, onset, and side-effect and interaction profile.
| Product | Dosing | Who it was/is for | Current status |
|---|---|---|---|
| Nirsevimab (Beyfortus) | One intramuscular injection: 50 mg under 5 kg or 100 mg at 5 kg or more for a first RSV season; 200 mg, given as two 100 mg injections, for a second season in eligible children 8 to 19 months | First season: infants younger than 8 months whose mother did not receive RSV vaccine, whose maternal vaccination status is unknown, or who were born within 14 days of vaccination. Selected high-risk children ages 8 to 19 months qualify for a second season. | Currently available. FDA trials found roughly a 70% reduction in medically attended RSV lower respiratory infection in preterm infants and about 75% in term or late-preterm infants, compared with placebo |
| Palivizumab (Synagis) | Five once-monthly intramuscular injections at 15 mg per kilogram, repeated across a single RSV season | Historically reserved for a narrower high-risk group under AAP guidance, including certain infants born very preterm, those with chronic lung disease of prematurity, and those with hemodynamically significant congenital heart disease | No longer available in the United States as of December 31, 2025. Historical palivizumab eligibility does not automatically establish current second-season eligibility for another product. |
- The FDA approved nirsevimab (Beyfortus) on July 17, 2023, for reducing the chance of RSV lower respiratory tract disease in neonates, infants entering their first RSV season, and children up to 24 months who remain vulnerable through a second season, given as a single intramuscular injection before or during the season. 1
- In FDA trials, nirsevimab reduced medically attended RSV lower respiratory infection by approximately 70% in preterm infants and approximately 75% in term and late-preterm infants compared with placebo, and a separate active-controlled trial against palivizumab supported its use in more vulnerable children too. 1
- CDC first-season recommendations consider maternal RSV vaccination as well as age and season. Most infants born at least 14 days after maternal vaccination do not need an infant antibody. When indicated, nirsevimab dosing is weight-based in the first season; selected high-risk children ages 8 to 19 months receive 200 mg for the second season. 2
- The second-season, increased-risk group eligible for another nirsevimab dose includes children with chronic lung disease of prematurity who still need medical support, severe immunocompromise, cystic fibrosis meeting specific criteria, and American Indian or Alaska Native children. 2
- Palivizumab was historically given as five once-monthly intramuscular doses of 15 mg/kg across a single RSV season, and CDC guidance now states plainly that starting December 31, 2025, palivizumab will no longer be available in the United States, with the guidance instead built around nirsevimab and clesrovimab. 2
- Clesrovimab, approved in 2025, is an alternative long-acting antibody for eligible infants entering their first RSV season, given as one 105 mg dose regardless of weight. It is not a second-season option. Nirsevimab remains the antibody used for selected high-risk children entering a second season. 3
- RSV is described by CDC as the leading cause of infant hospitalization in the United States and the most common cause of bronchiolitis and pneumonia in children younger than 1, with infants under 6 months especially vulnerable to illness severe enough to need hospitalization. 4
Which option makes sense?
Options in this comparison can differ substantially in suitability. Please consult your healthcare provider to interpret the evidence, limitations, and cautions before choosing an option or changing your plan.
Disclosure: Pregnancy Smart is a supplement maker. The options compared above sit outside our own product line; this page describes their pregnancy evidence on its own merits.
Frequently asked questions
Is palivizumab still an option for my baby?
Palivizumab is no longer available in the United States. Your pediatrician should reassess current eligibility. Nirsevimab and clesrovimab are first-season options when an infant antibody is indicated, but only nirsevimab is recommended for selected high-risk children entering a second season.
Why did my older child get monthly Synagis shots while my new baby only needs one shot?
Palivizumab required repeated monthly doses in a narrower high-risk group. Longer-acting antibodies changed that schedule. A current baby still needs an individual eligibility check that includes age, season, maternal RSV vaccination, and any qualifying second-season risk factors.
What was actually different about how the two worked?
Palivizumab needed monthly redosing, five doses at 15 mg/kg across a season, because its protection didn't last as long. Nirsevimab is engineered for extended protection from one dose, which is what allows a single injection to cover an entire RSV season instead of a repeating monthly series.
Does a previous Synagis recommendation guarantee another RSV antibody now?
No. Products and eligibility rules have changed. A clinician should use the current CDC criteria rather than automatically transferring an older palivizumab plan, particularly for a second RSV season.
My baby was born with a heart or lung condition. Does nirsevimab still cover her?
A heart or lung condition calls for an individual review, not an automatic yes. Current second-season criteria include particular chronic lung disease, immune, cystic-fibrosis, and other defined risk groups. Congenital heart disease alone is not listed as a blanket second-season qualification. Discuss the exact condition and season with the specialist.
What is clesrovimab, and how is it different from nirsevimab?
Clesrovimab is a long-acting antibody for eligible infants entering their first RSV season. It uses one 105 mg dose regardless of weight. Nirsevimab is also used in the first season and is the antibody recommended for selected high-risk children entering a second season.
How much does an RSV antibody shot actually lower the risk of severe illness?
In FDA trial data for nirsevimab, medically attended RSV lower respiratory infection was reduced by about 70% in preterm infants and about 75% in term or late-preterm infants compared with infants who didn't receive it. That's a substantial drop in the kind of RSV illness serious enough to need medical care.
Does my baby need an RSV antibody shot if an older sibling never got one?
A sibling's history does not determine eligibility. Bring the mother's RSV vaccination date to the pediatric visit. Most babies born at least 14 days after maternal vaccination do not also need an infant antibody, although uncommon exceptions can apply. Age, season, and the child's own medical history also matter.
Related in the library
Comparisons
RSV vaccine in pregnancy vs baby's antibody shot
Symptoms
RSV in Babies: Warning Signs and When to Seek Care
Comparisons
RSV vs. Cold vs. Flu in Babies: How to Tell Them Apart
Is it safe?
Is RSV vaccine safe during pregnancy?
Is it safe?
Late Preterm Baby Feeding: Intake and Follow-Up
Is it safe?
Is flu shot safe during pregnancy?
Is it safe?
Is preparing for a possible NICU stay safe during pregnancy?
References
FDA Approves New Drug to Prevent RSV in Babies and Toddlers
FDA · https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-prevent-rsv-babies-and-toddlers
RSV Immunization Guidance for Infants and Young Children
CDC · https://www.cdc.gov/rsv/hcp/vaccine-clinical-guidance/infants-young-children.html
CDC · https://www.cdc.gov/mmwr/volumes/74/wr/mm7432a3.htm
CDC · https://www.cdc.gov/rsv/about/index.html
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.